Janssen Pharmaceutica N.V. To Present New Simeprevir Data At The International Liver Congress™ 2014 Of The European Association For The Study Of The Liver (EASL)
CORK, Ireland--(BUSINESS WIRE)--New data from the clinical development programme for Janssen’s protease inhibitor simeprevir in the treatment of genotype 1 or genotype 4 chronic hepatitis C virus (HCV) in adult patients with compensated liver disease will be presented at The International Liver Congress™ of the European Association for the study of the Liver (EASL). The International Liver Congress™ 2014 will take place from April 9-13 in London.
Help employers find you! Check out all the jobs and post your resume.